Veno occlusive disease uptodate

Get the latest MTG Singles. Free Shipping available on US card orders $25 Largest selection of incontinence products with fast and discreet shipping nation-wide. Healthwick's caring team offers knowledge, products, and service to manage incontinence {{configCtrl2.info.metaDescription} Hepatic sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease (VOD), is a systemic endothelial disease that typically presents in the days or weeks after hematopoietic cell transplantation (HCT) with refractory thrombocytopenia, hepatomegaly, ascites, and jaundice, and it can rapidly progress to multiorgan dysfunction and death

called veno - occlusive disease (VOD), develops in up to 15 percent of adults after hematopoietic cell transplantation (HCT). The incidence of SOS varies with the patient population, classical SOS (ie, <21 days from HCT) and late-onset SOS (ie, ≥21 days after transplantation) INTRODUCTION. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis (PVOD/PCH) are now considered the same disease. PVOD/PCH is a rare condition that represents a small subgroup of adult patients with pulmonary hypertension (PH) [].The terms isolated pulmonary venous sclerosis, obstructive disease of the pulmonary veins, and venous form of primary pulmonary hypertension. Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) is a rare condition that represents a subgroup of patients with pulmonary hypertension (table 1). In general, PVOD progresses rapidly such that early recognition and treatment of this entity is critical Hepatic veno-occlusive disease (VOD) is one of the most serious complications following hematopoietic stem cell transplantation (SCT) and is associated with a very high mortality in its severe form. This review outlines the pathogenesis and clinical features of VOD, with an emphasis on endothelial cell injury and risk factors UpToDate, electronic clinical resource tool for physicians and patients that provides information on Adult Primary Care and Internal Medicine, Allergy and Immunology, Cardiovascular Medicine, Emergency Medicine, Endocrinology and Diabetes, Family Medicine, Gastroenterology and Hepatology, Hematology, Infectious Diseases, Nephrology and.

Types: Skin Care, Cosmetics, Hair Car

UpToDate, Waltham, MA, USA. Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008;50:831-2. Senzolo M et al. Veno occlusive disease: Update on clinical management Pulmonary veno-occlusive disease (PVOD) is defined by specific pathologic changes of the pulmonary veins. A definite diagnosis of PVOD thus requires a lung biopsy or pathologic examination of pulmonary explants or postmortem lung samples Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell transplantation (HCT) conditioning or non-transplant.

SkinStore - Premium Skin Care Online - Free Shipping Over $4

Initial experimental efforts to induce veno-occlusive disease in animals focused on irradiation. Although the non-human primate liver is relatively resistant to radiation-induced veno-occlusive disease, 25 veno-occlusive lesions could be induced in primates 26 and in non-primates 27 by exposure to chronic irradiation regimes Definition of abbreviations: HIV = human immunodeficiency virus; WHO = World Health Organization. Pulmonary veno-occlusive disease (PVOD) is a clinicopathologic syndrome that accounts for a small number of cases of pulmonary hypertension Imaging description Pulmonary veno-occlusive disease (PVOD) is considered a cause of pulmonary hypertension that preferentially affects the post-capillary pulmonary vasculature. The pathologic hallmark of PVOD is the extensive and diffuse occlusion of pulmonary veins by fibrous tissue. The imaging findings are a result of this fibrotic occlusion Pulmonary edema in patients with pulmonary veno-occlusive disease. If confirmed, discontinue treatment. 1) -----ADVERSE REACTIONS-----­ Adverse reactions occurring more frequently (≥5%) on UPTRAVI compared to placebo are headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing

Previously called veno-occlusive disease (Semin Liver Dis 2002;22:27) Sometimes called blue liver syndrome ICD coding. ICD-10: K76.5 - Hepatic veno-occlusive disease Pathophysiology. Toxic agent damages sinusoidal endothelial cells, likely via depletion of glutathione and nitric oxid Pulmonary veno-occlusive disease (PVOD) is a rare condition with poor prognosis, and lung transplantation is recommended as the only curative therapy. The role of pulmonary arterial hypertension targeted therapy in PVOD remains controversial, and long-term effects of targeted therapy have been rarely reported Anticancer drugs have improved mortality rates and 5-year survival rates in patients with cancer, however, many of the modern chemotherapies are associated with cardiovascular toxicities that increase cardiovascular risk in cancer patients, including the development of hepatic veno-occlusive disease in certain cases

Pulmonary veno-occlusive disease (PVOD) and/ or pulmonary capillary hemangiomatosis (PCH) My doctor says I have PVOD. What is this? As the name suggests Pulmonary veno-occlusive disease (PVOD) uniquely involves the small veins of the lung circulation more than the small arteries. The veins become blocked with scar tissue that is not normally present. Sometimes PVOD [ veno-occlusive disease A liver disorder in which the small branches of the hepatic vein within the liver become obliterated, but not by blood clotting. The condition can be caused by drinking 'bush tea' containing pyrrolizidine alkaloids, and in other ways

{{configCtrl2.info.metaDescription}} This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies Veno-occlusive disease is believed to be caused by injury to the hepatic venous endothelium during HSCT conditioning,2 leading to sinusoidal obstruction.1 Diagnosis is based on a combination of the following signs and symptoms: (1) jaundice or elevated serum bilirubin levels, (2) hepatomegaly with right upper quadrant abdominal pain, and (3.

Find the best deals on trollandtoad

Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134:809. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078 UPTRAVI® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms

Video: Largest buyer of HeroClix · Game On; MTG, Yugioh more · Since 199

Brands: Magic: The Gathering, Yu-Gi-Oh, Pokémo

  1. Hepatic veno-occlusive disease (hepatic VOD) is a condition resulting from toxic injury to the hepatic sinusoidal capillaries that leads to obstruction of the small hepatic veins. Epidemiology. Prevalence is unknown but hepatic VOD is a rare disease. Endemic zones have been identified in which the disease is associated with the consumption of.
  2. UpToDate performs a continuous review of over 330 journals and other resources. Updates are added as important new information is published. Symptoms, diagnosis, and treatment of the Budd-Chiari syndrome and see Pathogenesis and clinical features of hepatic veno-occlusive disease following hematopoietic cell transplantation)
  3. Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±
  4. Pulmonary veno-occlusive disease is a rare cause of pulmonary hypertension which is part, together with pulmonary capillary hemangiomatosis, of the special designation (subgroup 1') within pulmonary hypertension group 1 in the latest classification of the pulmonary hypertension World Symposium

Exotic Disease-Planeshift-Magi

  1. al hepatic veins or the small hepatic vein system inside the liver. The larger branches of the hepatic vein system are not involved. Obstruction of the flow from the hepatic sinisoids, which results in liver cell damage
  2. The vaso-occlusive crisis, or sickle cell crisis, is a common painful complication of sickle cell disease in adolescents and adults. Acute episodes of severe pain (crises) are the primary reason.
  3. Paraneoplastic syndromes: e.g., Hodgkin disease, renal carcinoma Ductal plate malformations: e.g., congenital hepatic fibrosis Nodular regenerative hyperplasia Vascular disorders: e.g., BuddChiari syndrome, veno-occlusive disease, congestive hepatopathy Cirrhosis (any cause) Cholangiocellular cholestasis Primary biliary cirrhosis (AMA+/AMA_
  4. Heyde's syndrome is a syndrome of gastrointestinal bleeding from angiodysplasia in the presence of aortic stenosis.. It is named after Edward C. Heyde, MD, who first noted the association in 1958. It is caused by the induction of Von Willebrand disease type IIA (vWD-2A) by a depletion of Von Willebrand factor (vWF) in blood flowing through the narrowed valvular stenosis
  5. Q&A: Vascular Complications Of Cytotoxics: Pulmonary Veno-Occlusive Disease Last edited July 20, 2010. Development of new anticancer drugs has resulted in improved mortality rates and 5-year survival rates in patients with cancer. However, many of the modern chemotherapies are associated with cardiovascular toxicities that increase.

Guide to Compression Socks and Stockings - Healthwic

  1. Veno-occlusive disease. VOD was diagnosed using the standard Baltimore clinical criteria 5 of hyperbilirubinemia (bilirubin, > 34.2 μM[> 2 mg/dL]), accompanied by 2 or more of the following: painful hepatomegaly, fluid retention or ascites, or sudden weight gain (> 5% of baseline weight) in the absence of another explanation
  2. ute walking distance/6-
  3. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul;16(7):1005-17. doi: 10.1016/j.bbmt.2010.02.009. Epub 2010 Feb 16
  4. sis and pulmonary veno-occlusive disease. Pulmonary hypertension frequently occurs in response to alveolar hypoxia. A reduction in oxygen tension causes pulmonary vaso
  5. UpToDate 2018. Diagnostic studies •Liver blood tests •Microbiology tests -Antibodies, antigen, NAT, stains, cultures, skin testing, etc. •Imaging -US, CT, ERCP • Veno-occlusive disease/sinusoidal obstruction syndrome • Diffuse infiltration of the liver with cance
  6. ary evidence indicates promise in treating mixed arterial and veno-occlusive disease. Success rates for surgical procedures for veno-occlusive disease generally have been poor. Success rates within the first year range from 23% to 80% and consistently decrease with longer-term follow-up (14% to 77% at one year)
  7. SCORAD: Severity scoring of Alzheimer disease THI: Transient hypogammaglobulinemia VOD: Veno-occlusive disease WAS: Wiskott-Aldrich syndrome XLA: X-linked agammaglobulinemia artery aneurysms in Kawasaki disease (KD); (4) prevention of infections, pneumonitis, and acute graft-versus-host disease (GVHD) following bone marrow transplantation; (5.

UPTRAVI® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms Update on the use of immunoglobulin in human disease: A review of evidence Author links open overlay panel Elena E. Perez MD, PhD a Jordan S. Orange MD, PhD b Francisco Bonilla MD, PhD c Javier Chinen MD, PhD b Ivan K. Chinn MD b Morna Dorsey MD, MMSc d Yehia El-Gamal MD, PhD e Terry O. Harville MD, PhD f Elham Hossny MD, PhD e Bruce Mazer MD g. United States are hepatitis C, alcoholic liver disease, and nonalcoholic liver disease, which together accounted for approximately 80 percent of patients on the liver transplantation waitlist between 2004 and 2013 [1]

Gemtuzumab ozogamicin may cause serious or life-threatening liver problems, including veno-occlusive disease (blocked blood vessels in the liver that can lead to liver damage). You will need frequent medical tests. Your cancer treatments may be delayed based on the results Similarly, other conditions may mimic classic pulmonary-renal syndrome such as severe mitral stenosis or pulmonary veno-occlusive disease with pulmonary edema and a low cardiac output state, drug toxicity (i.e., cocaine, sirolimus), primary pulmonary infection or severe sepsis, and any cause of ARF with uremic-induced increases in pulmonary.

Erythromelalgia or Mitchell's disease (after Silas Weir Mitchell), is a rare vascular peripheral pain disorder in which blood vessels, usually in the lower extremities or hands, are episodically blocked (frequently on and off daily), then become hyperemic and inflamed. There is severe burning pain (in the small fiber sensory nerves) and skin redness. The attacks are periodic and are commonly. The hepatic veno-occlusive disease as a form of hepatic veno-occlusive disease or VOD (also Hepatic sinusoidal obstruction syndrome, SOS is known) the result of (incomplete) closure of the small hepatic veins.It is similar to liver failure with ascites, liver enlargement and an increase in the bilirubin level in the blood.. The disease usually occurs as a complication of a higher dose of.


  1. Patients with hepatic veno-occlusive disease present with painful hepatomegaly, jaundice, and retain fluid.3 Another diagnosis to consider is drug toxicity from chemotherapeutic drugs, corticosteroids, antibiotics, antifungal agents, and anti-GVHD drugs.1 Biopsy is the definitive method to diagnose GVHD o
  2. ed the incidence of pulmonary edema after initiation of prostacyclin therapy
  3. The OPTN is operated under contract with the U.S. Dept. of Health and Human Services by the United Network for Organ Sharing (UNOS). This Web site provides data and educational information about organ donation, transplantation and the matching process
  4. al aorta (AA) and superior mesenteric artery (SMA), although other variants exist. The name derives from the fact that, in the sagittal plane and/or transverse plane, the SMA and AA (with some imagination) appear to be a nutcracker crushing a nut (the renal vein)
  5. מחלה חסימתית של ורידי הכבד (אנגלית: ‏Veno-Occlusive Disease; בקיצור - VOD, נקראת גם Sinusoidal Obstruction Syndrome) היא מחלה נדירה ומסכנת חיים, המופיעה בחולים מושתלי מח עצם כ-30 יום לאחר ההשתלה. בבסיס המחלה פגיעה אנדותליאלית בכבד, המובילה לחסימה.
  6. Budd-Chiari syndrome is a rare disorder caused by hepatic venous outflow obstruction and resulting hepatic dysfunction. Despite a lack of prospective randomized trials, much progress has been.

Hepatic venoocclusive disease (HVOD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) and is a well-recognized dose-limiting toxicity of oral busulfan (Bu)-based preparative regimens. The unpredictable absorption of oral Bu from the gastrointestinal (GI) tract and hepat Severe side effects of Mylotarg include low blood counts, infections, liver damage, blockage of the veins in the liver (hepatic veno-occlusive disease), infusion-related reactions, and severe. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30:850-7. Montani D, Achouh L, Dorfmuller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology Severe liver damage, including veno-occlusive disease (blockage of veins in the liver) Reactions during the infusion (similar to an allergic reaction). You will likely be given medicines before each infusion to help prevent this. Serious or life-threatening infections, especially in people who have already had a stem cell transplan Postcholecystectomy syndrome (PCS) describes the presence of abdominal symptoms after a cholecystectomy (gallbladder removal).. Symptoms occur in about 5 to 40 percent of patients who undergo cholecystectomy, and can be transient, persistent or lifelong. The chronic condition is diagnosed in approximately 10% of postcholecystectomy cases

Portal hypertension refers to a pathological elevation of portal venous pressure resulting from obstructions in portal blood flow, which may be either prehepatic (e.g., portal vein thrombosis), hep.. PAH is a rare and fatal disease estimated to affect 10 to 12 per one million Americans. 3 Risk factors include connective tissue diseases, congenital heart disease, portal hypertension, HIV infection, and certain drugs and toxins (e.g., aminorex, amphetamines, fenfluramine, dexfenfluramine, L-tryptophan, toxic rapeseed oil). 4 Obesity and use. We are open for safe in-person care. Learn more: Mayo Clinic facts about coronavirus disease 2019 (COVID-19) Our COVID-19 patient and visitor guidelines, plus trusted health information Latest on COVID-19 vaccination by site: Arizona patient vaccination updates Arizona, Florida patient vaccination updates Florida, Rochester patient vaccination updates Rochester and Mayo Clinic Health System.

Uncommon (0.1% to 1%): Capillary leak syndrome, veno-occlusive disease. Rare (0.01% to 0.1%): Aortitis, vascular disorder . Genitourinary. Common (1% to 10%): Dysuria, hematuria, urinary tract infection. Uncommon (0.1% to 1%): Proteinuria, Rare (0.01% to 0.1%): Urine abnormality . Loca The role of glutamine in the prevention of chemotherapy and radiation-induced toxicity is evolving. Glutamine supplementation is inexpensive and it may reduce the incidence of gastrointestinal, neurologic, and possibly cardiac complications of cancer therapy. Further studies, particularly placebo-co

Hepatic veno-occlusive disease: pathogenesis, diagnosis

Dyspnea, also known as shortness of breath or breathlessness, is a subjective sensation of breathing discomfort. It is a common symptom, present in up to half of patients admitted to acute, tertiary care hospitals and in one quarter of medical outpatients. Dyspnea accounts for approximately 3.4. Mohty M, Malard F, Abecasis M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020;55:485-495 Profile: Dr. Clardy is an attending physician in the Division of Pulmonary, Critical Care and Sleep Medicine at Beth Israel Deaconess Medical Center, where he serves as the Director of Medical Intensive Care.His research and clinical interests include the genetic epidemiology of ARDS, transfusion practice, patient safety and healthcare quality Acute liver failure is a broad term that encompasses both fulminant hepatic failure (FHF) and subfulminant hepatic failure (or late-onset hepatic failure). Fulminant hepatic failure is generally used to describe the development of encephalopathy within 8 weeks of the onset of symptoms in a patient with a previously healthy liver Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual. A patient is deemed to have pulmonary hypertension if the pulmonary mean arterial pressure.

Sinusoidal Obstruction Syndrome (Veno-occlusive Disease

Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. Lassau N, Leclere J, Auperin A, Bourhis JH, Hartmann O, Valteau-Couanet D, Benhamou E, Bosq J, Ibrahim A, Girinski T, Pico JL, Roche Introduction. Veno-occlusive disease (VOD) is a severe complication of allogeneic stem cell transplantation (allo-SCT) and often has a lethal outcome (Corbacioglu et al. 2018).Mortality in severe cases of VOD reaches 80% (Dalle and Giralt 2016; Corbacioglu et al. 2018).The incidence of VOD after allo-SCT is highly variable, but a meta-analysis suggests an incidence of approximately 15% (Helmy. (hepatic veno-occlusive disease), graft-versus-host disease (GVHD) and medications Immune (alloimmunization) •Development of anti-human leukocyte antigen (HLA-I) and/or human platelet antigens UpToDate An Approach to the Patient Refractory to Platelets Transfusio

Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine 2008 ; 87 : 220 - 233 . OpenUrl CrossRef PubMed Web of Scienc Furthermore, an UpToDate review on Treatment of acne vulgaris (Graber, 2019) states that Oral glucocorticoids (typically, prednisone 0.5 to 1 mg/kg per day) and oral isotretinoin are the mainstays of treatment for acne fulminans. Thiopurines have been associated with veno-occlusive disease, regenerative nodular hyperplasia, and.

Libraries. The Robert M. Bird Health Sciences Library serves the Health Sciences Center and health professionals across the state, providing mediated searching, journal photocopying and access to the largest collection of medical books in Oklahoma. The Schusterman Library is the home library for Health Science Center degree students, resident. Pulmonary-renal syndromes (PRS) are defined by the combination of diffuse alveolar haemorrhage and glomerulonephritis.1, 2 The three most common causes of PRS presenting to the respiratory physician are ANCA-positive small vessel vasculitis, anti-glomerular basement membrane (anti-GBM) disease (Goodpasture's disease) and Systemic Lupus Erythematosus (SLE) Symptoms and Signs of Sinusoidal Obstruction Syndrome. Initial manifestations include sudden jaundice, ascites, and tender, smooth hepatomegaly. Onset is within the first 3 weeks of transplantation in bone marrow or hematopoietic cell recipients, who either recover spontaneously within a few weeks (or sometimes, with mild cases, after an. Wolman disease (WD) is an autosomal recessive storage disorder caused by very low (or absent) lysosomal acid lipase (LAL) activity. Deficiency of this enzyme leads to massive intracellular accumulation of cholesteryl esters and triglycerides. WD represents the severe form of LAL deficiency in which patients present in early infancy with.

Hepatic veno-occlusive disease Genetic and Rare Diseases

Idiopathic pulmonary hemosiderosis (IPH) is a rare disease of unknown etiology, characterized by recurrent episodes of diffuse alveolar hemorrhage and sideropenic anemia. IPH occurs most commonly in children. During an acute episode, a constellation of cough, dyspnea, and hemoptysis with alveolar infiltrates and worsening anemia should raise. Veno-occlusive disease: Congenital cardiopathy: Congestive heart failure: Constrictive pericarditis: Other: Fatty liver disease, Neonatal hepatitis, Zellweger disease: Biliary atresia. Biliary atresia (BA) occurs exclusively in childhood, and is the most common cause of chronic cholestasis and liver transplantation in children.. Hepatic veno-occlusive disease (VOD), now more frequently called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication that can occur after hematopoietic stem cell transplant (HSCT). Although rare, SOS/VOD has been associated with gemtuzumab ozogamicin therapy in patients with AML Dr. Bonis is the Chief Medical Officer of the Division of Clinical Effectiveness at Wolters Kluwer Health, which includes UpToDate, Clinical Drug Information and Emmi Solutions. He oversees content development, product strategy, innovation, and strategic partnerships, particularly with electronic medical record vendors VELETRI should not be used chronically in patients who during dose initiation develop pulmonary edema, which may be associated with pulmonary veno-occlusive disease. VELETRI is also contraindicated in patients with known hypersensitivity to the drug or to structurally related compounds

Thus, if a patient has symptoms or pulmonary hypertension out of proportion to the noninvasive measurements, cardiac catheterization is important to determine whether pulmonary hypertension is secondary to the mitral stenosis, left ventricular diastolic dysfunction, pulmonary veno-occlusive disease, or intrinsic pulmonary vascular disease The serum ascites albumin gradient (SAAG) is a formula that is used to assist in determining the cause of ascites.Ascites is an abnormal accumulation of fluid within the (peritoneal) cavity. One of the most common liver diseases is caused by cirrhosis of the liver but it can also be caused by other diseases Mesenteric artery thrombosis (MAT) is a condition involving occlusion of the arterial vascular supply of the intestinal system. It is a severe and potentially fatal illness typically of the superior mesenteric artery (SMA), which provides the primary arterial supply to the small intestine and ascending colon.[1] The occlusion may occur due to in-situ thrombosis of the vessel, most commonly due. Because the disease process is limited to the mucosa in patients with ulcerative colitis and is often transmural in Crohn's disease, bowel wall thickening is usually greater in Crohn's disease. One study found the mean thickness of the colon wall in Crohn's disease was 11.0 mm compared with 7.8 mm in patients with ulcerative colitis [ 23. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed April 2016. Das K, Kar P. Hepatopulmonary syndrome. J Assoc Physicians India. 2002;50:1049-1056. de Rave S, Hansen BE, Groenland TH, et al. Heterotopic vs. orthotopic liver transplantation for chronic liver disease: A case-control comparison of short-term and long-term outcomes

Unilateral noncardiogenic pulmonary edema may be caused by conditions ipsilateral to the edema such as aspiration, contusion, reexpansion, and pulmonary vein occlusion (eg, veno-occlusive disease or extrinsic compression) and by conditions contralateral to the edema such as pulmonary embolism and lobectomy [6] Veno-occlusive disease (VOD) occurred in 4 (8 %) patients; 6 (12 %) patients died from AEs that were deemed treatment related (5 [10 %] from sepsis and 1 [2 %] from VOD). The authors concluded that inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy was a safe and active 1st-line therapeutic option in older patients with newly diagnosed ALL. Cirrhosis is the end result of any progressive liver disease. Injury to individual hepatocytes can result from viral infection, drugs or toxins, hypoxia, immunologic disorders, or inborn errors of metabolism. The evolving process leads to repair, continuing injury with chronic changes, or, in rare cases, to massive hepatic damage Frequency not reported: Hepatic veno-occlusive disease, hepatitis . Musculoskeletal. Frequency not reported: Neurotoxicity is the most common dose-limiting side effect of this drug. Frequently, there is a sequence to the development of neuromuscular side effects. Initially, only sensory impairment and paresthesia. may develop Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis.Further slow damage to the liver tissue can lead to scarring, fibrosis, and eventually cirrhosis Huertas A, Girerd B, Dorfmuller P. et al. Pulmonary veno-occlusive disease: advances in clinical management and treatments. Expert Review of Respiratory Medicine, Apr 2011, Vol. 5, No. 2, Pages 217-231